Format

Send to

Choose Destination
J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Nov 15;875(2):373-82. doi: 10.1016/j.jchromb.2008.09.013. Epub 2008 Sep 19.

A high-performance liquid chromatography-tandem mass spectrometry method for the clinical combination study of carboplatin and anti-tumor agent eribulin mesylate (E7389) in human plasma.

Author information

1
Drug Safety and Disposition, Eisai Research Institute, 4 Corporate Drive, Andover, MA 01810, USA.

Abstract

An LC/MS/MS method was developed to quantify carboplatin and eribulin mesylate (E7389) in human plasma and urine. For carboplatin, sample clean-up by protein precipitation and supernatant injection into a Waters Spherisorb((R)) S5 SCX column was used. Liquid-phase extraction and reverse-phase chromatography on a Polaris C18 column were used for eribulin. Quantitation involved LC/MS/MS with positive electrospray ionization. Accuracy, precision, linearity, range, specificity, recovery and stability were also evaluated. Both compounds were stable in human plasma (>or=80 days at -80 degrees C), at room temperature (>or=4h), following three freeze-thaw cycles and in 50/50 methanol/H(2)O (<4 degrees C for >or=252 days).

PMID:
18835754
DOI:
10.1016/j.jchromb.2008.09.013
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center